Grants and Contributions:
The investment will allow the company to produce monoclonal antibody therapies in Val-des-Sources then fill and package them in St-Hubert.
Please note this update includes a change to improve standardization of reporting across projects. The end date was updated from the end of the work phase (31/03/2026) to the current end date of (02/07/2050). This is not an extension. The end date now reflects the entirety of the agreement duration, including the benefit phase and residual audit period. The original start date was updated to reflect the correct execution date.
Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.